Protopic Ointment in Adult Atopic Eczema of the Face - Full Text View

Sponsored by:	Astellas Pharma Inc
Information provided by:	Astellas Pharma Inc
ClinicalTrials.gov Identifier:	NCT00690105

Purpose

Patients with facial atopic eczema and a poor response to topical corticosteroid applied either Protopic or Fluticasone ointment twice a day for 3 weeks.

They could continue during 3 more weeks once a day if needed or change for the other ointment.

Condition	Intervention	Phase
Dermatitis, Atopic	Drug: tacrolimus 0.1% Drug: fluticasone 0.005 %	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study
Official Title:	Comparative, Multicentre, Randomized, Double-Blind Study to Assess the Efficacy of Tacrolimus 0.1% Ointment Versus Fluticasone 0.005% Ointment in Adult Patients Suffering From Moderate to Severe Atopic Dermatitis and Presenting With so-Called 'Red Face' Lesions of the Head and Neck.

Resource links provided by NLM:

MedlinePlus related topics: Eczema

Drug Information available for: Fluticasone propionate Fluticasone Tacrolimus anhydrous Tacrolimus

U.S. FDA Resources

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:

Percentage of patients presenting at the week 3 visit (day 21) with an improvement of at least 60% in their local mEASI score (mLEASI) compared to Baseline (day 1). [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Percentage of patients no longer presenting with 'facial' erythema at day 7 and day 21 [ Time Frame: 1 week and 3 weeks ] [ Designated as safety issue: No ]
Assessment of facial pruritus at day 1, day 7 and day 21 [ Time Frame: 1 week and 3 weeks ] [ Designated as safety issue: No ]
Global assessment of clinical response on the 'face' by the physician at day 7 and day 21 [ Time Frame: 1 week and 3 weeks ] [ Designated as safety issue: No ]
Global assessment of clinical response on the 'face' by the patient at day 7 and day 21 [ Time Frame: 1 week and 3 weeks ] [ Designated as safety issue: No ]
Patient's quality of life at day 1 and day 21 [ Time Frame: 1 week and 3 weeks ] [ Designated as safety issue: No ]
mLEASI score values at day 7 and day 21 [ Time Frame: 1 week and 3 weeks ] [ Designated as safety issue: No ]
Physician's assessment of individual signs [ Time Frame: 1 week and 3 weeks ] [ Designated as safety issue: No ]
Quality of sleep at day 1, day 7 and day 21 [ Time Frame: 1 week and 3 weeks ] [ Designated as safety issue: No ]
Affected surface area assessment at day 1, day 7 and day 21 [ Time Frame: 1 week and 3 weeks ] [ Designated as safety issue: No ]
Number of patients using the ointment from the other group to treat facial lesions after day 21 [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
Incidences of adverse events during the study period [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Enrollment:	577
Study Start Date:	February 2004
Study Completion Date:	July 2005
Primary Completion Date:	July 2005 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Experimental	Drug: tacrolimus 0.1% ointment
B: Active Comparator	Drug: fluticasone 0.005 % ointment

Detailed Description:

Treatments were to be applied twice daily over all lesions on the face (except for the eyelids) until clearance, for a maximum of 3 weeks and then, in case of uncleared residual lesions, once daily for up to 3 further weeks. In the event of a flare-up the treatment was to be resumed twice a day until the end of the study.

Eligibility

Ages Eligible for Study:	16 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Moderate to severe AD (Rajka & Langeland score) with lesions to the head and neck defined as 'red face' or 'facial eczema': erythema affecting at least 10% of the surface of the 'face' (head, neck, chest, nape of neck), due to long-term AD
At least two flare-ups of 'facial' eczema during the 12 months prior to inclusion and, in the investigator's opinion, conventional treatment had proved ineffective or poorly tolerated
Female patients of childbearing age: effective means of contraception throughout the period of the study and for four weeks following the end of the study
Informed consent
Therapeutic washout for atopic dermatitis treatments

Exclusion Criteria:

Genetic epidermal barrier defect, such as Netherton's syndrome, or suffering from erythroderma
Seborrheic dermatitis or contact dermatitis affecting the 'face', or any other facial erythema of non-atopic origin
Clinical infection due to the VZV virus (varicella, zona), HSV1-2 viruses (herpes), verruca vulgaris or molluscum contagiosum
Superinfected eczema
Known hypersensitivity to macrolides or to any other excipient in tacrolimus 0.1% ointment
Known hypersensitivity to one of the agents contained in the fluticasone 0.005% ointment preparation
Ulcerated lesions, of whatever type
Moderate to severe acne or rosacea
Patients who participated at the same time in another clinical study or who had participated in another clinical study within 28 days prior to inclusion in the study
Any type of substance abuse (including that of drugs and alcohol) or any mental disorder/psychological state which, in the investigator's opinion, might interfere with the patient's follow-up
Serologically-proven HIV positivity

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00690105

Locations

France

Nice, France, 06202

Sponsors and Collaborators

Astellas Pharma Inc

Investigators

Study Director:

Central Contact

Astellas Pharma Europe BV

More Information

Additional Information:

Link to results on ClinicalStudyResults.org This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Astellas Pharma Europe BV ( Disclosure Office Europe )
Study ID Numbers:	FG-506-06-FR-04, EUDRACT #: 2004-002477-23
Study First Received:	June 2, 2008
Last Updated:	December 4, 2008
ClinicalTrials.gov Identifier:	NCT00690105 History of Changes
Health Authority:	France: Afssaps - French Health Products Safety Agency; Belgium: Federal Agency for Medicinal Products and Health Products; Finland: National Agency for Medicines; Tunisia: Office of Pharmacies and Medicines; Morocco: Ministry of Public Health; Romania: National Medicines Agency

Keywords provided by Astellas Pharma Inc:

Dermatitis, Atopic
Dermatologic Agents
Topical Drug Administration
Tacrolimus

Calcineurin
Corticosteroid
Fluticasone propionate
Face

Study placed in the following topic categories:

Anti-Inflammatory Agents
Dermatitis, Atopic
Immunologic Factors
Facies
Skin Diseases
Anti-Asthmatic Agents
Anti-Allergic Agents
Eczema
Tacrolimus
Immunosuppressive Agents

Hypersensitivity
Genetic Diseases, Inborn
Hypersensitivity, Immediate
Skin Diseases, Eczematous
Fluticasone
Peripheral Nervous System Agents
Skin Diseases, Genetic
Bronchodilator Agents
Dermatitis

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Respiratory System Agents
Dermatitis, Atopic
Immunologic Factors
Skin Diseases
Immune System Diseases
Physiological Effects of Drugs
Anti-Asthmatic Agents
Anti-Allergic Agents
Tacrolimus
Immunosuppressive Agents
Pharmacologic Actions

Hypersensitivity
Genetic Diseases, Inborn
Autonomic Agents
Therapeutic Uses
Hypersensitivity, Immediate
Skin Diseases, Eczematous
Fluticasone
Peripheral Nervous System Agents
Dermatologic Agents
Skin Diseases, Genetic
Bronchodilator Agents
Dermatitis

ClinicalTrials.gov processed this record on July 06, 2009